StockNews.com Initiates Coverage on RedHill Biopharma (NASDAQ:RDHL)

StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note issued to investors on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Trading Up 2.2%

Shares of RDHL opened at $1.85 on Friday. RedHill Biopharma has a 52 week low of $1.71 and a 52 week high of $20.28. The stock has a 50 day moving average of $2.36 and a 200-day moving average of $4.87.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.